LAUSR

of the Journal , Montani and colleagues report results from the largest national prospective cohort study of patients with PH who received diagnoses of COVID-19, wherein they observed high rates of hospitalization (60%) and in-hospital mortality (41.3%). Patients at highest risk of dying were male, older, had more severe baseline PH, and were more medically comorbid. Pulmonary vasodilator therapies did not protect against in-hospital death, but patients on baseline anticoagulation were more likely to survive their hospitalization. This study establishes that patients with precapillary PH are at increased risk of adverse clinical outcomes from COVID-19, underscoring the public health importance of preventive measures in this high-risk population. CTEPH=chronic thromboembolic pulmonary hypertension; PAH=pulmonary arterial hypertension. Illustration by Jill Gregory.